iGENETECH Announces Global IVD Market Entry Strategy: Accelerating Evidence-Based Expansion
iGENETECH has officially announced its global market access strategy for the IVD market, centered on its next-generation molecular diagnostic platforms MoiM Dx100 and MoiM Dx200.The strategy outlines a three-step execution plan aimed at capturing the rapidly growing near point-of-care (Near-PoC) molecular diagnostics market worldwide.1. Clinical EvidencePublication in Scientific Reports (February 2025), a journal within the Nature portfolio, demonstrated diagnostic performance comparable to gold-standard laboratory methods, providing early validation aligned with the requirements of global regulatory authorities and strengthening the company’s readiness for entry into highly regulated markets.2. Optimized PortfolioThe two-track platform lineup—MoiM Dx100 for small clinics and decentralized settings, and MoiM Dx200 for small-to-mid-sized hospitals and emergency departments—enables flexible adaptation to the diverse needs of healthcare systems across different countries and care environments.3. Strategic ReferencesThrough a government-supported commercialization program from the Ministry of Health and Welfare and collaborative research with Samsung Medical Center, iGENETECH is building top-tier clinical references to support the expansion of global partnerships.With validated technology and strong strategic references, iGENETECH aims to position itself as a game changer in the global healthcare diagnostics market.
iGENETECH has officially announced its global market access strategy for the IVD market, centered on its next-generation molecular diagnostic platforms MoiM Dx100 and MoiM Dx200.The strategy outlines a three-step execution plan aimed at capturing the rapidly growing near point-of-care (Near-PoC) molecular diagnostics market worldwide.1. Clinical EvidencePublication in Scientific Reports (February 2025), a journal within the Nature portfolio, demonstrated diagnostic performance comparable to gold-standard laboratory methods, providing early validation aligned with the requirements of global regulatory authorities and strengthening the company’s readiness for entry into highly regulated markets.2. Optimized PortfolioThe two-track platform lineup—MoiM Dx100 for small clinics and decentralized settings, and MoiM Dx200 for small-to-mid-sized hospitals and emergency departments—enables flexible adaptation to the diverse needs of healthcare systems across different countries and care environments.3. Strategic ReferencesThrough a government-supported commercialization program from the Ministry of Health and Welfare and collaborative research with Samsung Medical Center, iGENETECH is building top-tier clinical references to support the expansion of global partnerships.With validated technology and strong strategic references, iGENETECH aims to position itself as a game changer in the global healthcare diagnostics market.